The potential of the inodilator levosimendan in maintaining quality of life in advanced heart failure.

ABSTRACT: Maintaining adequate quality of life (QoL) is an important therapeutic objective for patients with advanced heart failure and, for some patients, may take precedence over prolonging life. Achieving good QoL in this context may involve aspects of patient care that lie outside the familiar limits of heart failure treatment. The inodilator levosimendan may be advantageous in this setting, not least because of its sustained duration of action, ascribed to a long-acting metabolite designated OR-1896. The possibility of using this drug in an outpatient setting is a notable practical advantage that avoids the need for patients to attend a clinic appointment. Intermittent therapy can be integrated into a wider system of outreach and patient monitoring. Practical considerations in the use of levosi

SUBMITTER: Nieminen MS 

PROVIDER: S-EPMC5932556 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature